Skip to Content

Join the 'Factor Ix Complex' group to help and get support from people like you.

Factor Ix Complex News

FDA Approves Alprolix (recombinant coagulation factor IX) for patients with Hemophilia B

Posted 28 Mar 2014 by Drugs.com

March 28, 2014 – The U.S. Food and Drug Administration today approved Alprolix, Coagulation Factor IX (Recombinant), Fc Fusion Protein, for use in adults and children who have Hemophilia B. Alprolix is the first Hemophilia B treatment designed to require less frequent injections when used to prevent or reduce the frequency of bleeding. Alprolix is approved to help control and prevent bleeding episodes, manage bleeding during surgical procedures, and prevent or reduce the frequency of bleeding episodes (prophylaxis). Alprolix consists of the Factor IX molecule linked to a protein fragment, Fc, which is found in antibodies. This makes the product last longer in circulation. “The approval of this product provides another therapeutic option for the treatment and prevention of bleeding in patients with Hemophilia B,” said Karen Midthun, M.D., director of the FDA’s Center for Biologics Ev ... Read more

Related support groups: Hemophilia B, Factor Ix Complex

Ask a Question

Further Information

Related Condition Support Groups

Factor VII Deficiency, Factor IX Deficiency, Hemophilia B, Hemophilia A with Inhibitors

Related Drug Support Groups

Proplex T, Bebulin, Bebulin VH, Konyne 80, Profilnine SD

Factor Ix Complex Patient Information at Drugs.com